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   SUMMARY 
 
Breast cancer is one of the most common cancer affecting 
especially women worldwide and it shows a particularly 
aggressive behavior in the triple negative (TNBC) and basal-like 
breast cancer (BLBC) subtypes that are characterized by poor 
prognosis and by the lack of targeted therapies. Moreover, it is 
well established that the presence of a massive leukocyte 
infiltrate, is involved in the promotion of tumor progression, 
contributing in particular to the angiogenic switch that occurs in 
the early phases of tumor progression. Among the variety of 
cells infiltrating breast tumors, macrophages have been 
extensively shown to tightly control the angiogenic onset and 
progression to malignancy. Here, we investigated whether ID4 
protein, previously reported to enhance the angiogenic potential 
of breast cancer cells, exerts its function also modulating the 
activity of tumor-associated macrophages. We first assessed the 
significant association between the expression of ID4 and the 
macrophages marker CD68 in series of triple negative breast 
tumors. Of note, high ID4 mRNA expression in presence of a 
high macrophage infiltrate (determined as the expression of 8 
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macrophage markers) in BLBC is a strong predictor of poor 
survival. In vitro and in vivo migration assays evidenced that 
expression of ID4 in breast cancer cells is able to influence 
macrophages motility. At gene expression level we observed 
induction of ID4 itself, in macrophages co-cultured with breast 
cancer cells, induction that was impaired when breast cancer 
cells were depleted of ID4 expression. The same ID4-dependent 
behavior was observed for HIF-1A and for an angiogenesis-
related signature in macrophages. Expression of angiogenesis-
related genes was further controlled by miR-107, down-
regulated in macrophages in ID4-dependent manner. Altogether 
our results highlight a key role for ID4 in dictating the 
angiogenic behavior of tumor-associated macrophages in breast 
cancer. 
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1. INTRODUCTION 
 
1.1 Breast cancer  
 
Breast cancer is one of the most common cancers in women 
worldwide, and one of the principal cancer death cause. Over 
1.5 million women (25% of all women with cancer) are 
diagnosed with breast cancer every year in the world 
(1)
. 
Survival rates for breast cancer vary worldwide, but in general 
outcomes have improved first of all thanks to the widespread 
use of mammographic screening that has increased the rate of 
early detection, especially in most developed countries 
(2)
,
 
and 
also thanks to the development of more effective adjuvant 
chemotherapeutic regimens and the extended use of endocrine 
therapies 
(3)
. 
Age, reproductive factors 
(4)
, personal or family history of breast 
disease
 (5)
, genetic pre-disposition 
(6)
, environmental factors, 
diet, alcohol, obesity, lifestyle, physical inactivity, as well as 
endocrine factors ( both endogenous and exogenous) have been 
associated with an increased risk for the development of female 
breast cancer
 (7) (8)
. Despite significant advances in diagnosing 
and treating breast cancer, it remains a complicated disease to 
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treat due to its highly heterogeneous nature at both the 
molecular and clinical level 
(9)
 
(10) 
.  
 
1.1.1 Breast cancer molecular classification 
 
The traditional breast cancer classification system includes  
immunohistochemistry (IHC) markers such as estrogen receptor 
(ER), progesteron receptor (PR) and human epidermal growth 
factor receptor 2 (HER-2), together with traditional 
clinicopathological variables as tumor size, tumor grade and 
nodal involvement
 (11)
. Although these parameters are used for 
patient management, however they are not sufficient to reflect 
the complexity of breast tumors, so many studies based on 
global gene expression analyses have provided additional 
insights, leading to the identification of  four molecular subtypes 
of breast cancer that show different behavior for incidence, 
survival and response to treatment (Luminal A, Luminal B, 
HER2-enriched and Basal-like) 
(12) (13)
. 
Indeed, the most robust distinction observed by microarray 
analysis is between the transcriptome of estrogen receptor-
positive (ER+) and estrogen receptor negative (ER-) breast 
cancers 
(14)
. Evaluation of ER status is indeed determinant to 
predict patients outcome and  response to therapy, in particular it 
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is important to determine the candidacy for endocrine therapy 
(ET) that is suitable for ER+ breast cancer patients in 
association with Tamoxifen 
(15) (16)
(Table 1). 
 
 
1.1.2 Estrogen receptor positive (ER+) tumors: Luminal 
A and Luminal B 
 
Luminal A and Luminal B tumors are both positive for the 
expression of the estrogen receptor and show expression 
patterns similar to „normal luminal epithelial cells‟ of the 
mammary gland, including low molecular weight cytokeratins 
8/18, ER and genes associated with ER pathway . The principal 
characteristic of this group is the luminal expression signature, 
composed of Estrogen receptor1 (ESR1), GATA3, Forkhead 
Box A1 (FOXA1), X-box binding protein 1 (XBP1), and cMYB  
(13) (17)
 
(18)
.
 
Luminal A tumors have been demonstrated to have low levels of 
proliferation related genes, be usually of low histological grade 
and have an excellent prognosis; whereas luminal B cancers are 
more often of higher histological grade, have higher 
proliferation rates and a significantly worse prognosis than 
luminal A tumours 
(13) (17) (19)
. 
 
Luminal A breast cancer subtypes 
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show frequent mutations for phosphoinositide-3-
kinase,catalytic,alpha polypeptide (PIK3CA), mitogen activated 
protein kinase kinase kinase- 1 (MAP3K1) and GATA-3, Tumor 
protein 53 (TP53), and cadherin 1 (CDH-1). The most frequent 
mutations in luminal B tumors are TP53, PIK3CA and  GATA-3 
(18)
.
 
 
1.1.3 Estrogen receptor negative tumors:  HER2 and 
basal-like breast cancer 
 
 The ER-negative group is significantly more heterogeneous and 
comprises two different subtypes, HER-2 and Basal-like breast 
cancer: 
1. HER2-positive cancers show amplification and high 
expression of the Human Epidermal Growth Factor 
Receptor 2  (HER-2 or ERBB-2). The HER-2 gene 
encodes a 185 kDa transmembrane protein that can 
acquire an active conformation, dimerizing with other 
epidermal growth factor receptors (EGFR) in a ligand 
independent manner; its overexpression is associated 
with a more aggressive disease, higher recurrence rate, 
and shortened survival 
(20)
. However, since its approval 
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in 1998, the HER-2 positive breast cancer can be treated 
with the monoclonal antibody Trastuzumab, that targets 
the HER-2 receptor and has become the standard of care 
for the treatment of HER-2 positive breast cancer 
improving outcomes for early stage as well as metastatic 
breast cancer
 (21)
 . 
2. The Basal-like and Triple negative breast cancer 
subtypes (BLBC, TNBC), that comprise a heterogeneous 
group accounting for up to 15% of all breast cancers, is 
very clinically interesting for its high frequency, lack of 
effective targeted therapies, poor prognosis, and the 
tendency to affect younger patients
 (22)
The BLBC and 
TNBC group is characterized by a high aggressiveness, 
with an high risk of  recurrence in the first 3 years and an 
high percentage of deaths in the first 5 years following 
therapy
 (12)
.The Basal-like subtype is often referred to as 
Triple-Negative Breast Cancers (TNBC) because most 
Basal-like tumors are typically negative for ER, PR and 
HER-2 expression. However, ~75% of TNBC are basal-
like with the other 25% comprised of all other mRNA 
subtypes including mostly HER2+ breast cancer 
including mostly HER2+ breast cancer 
(23)
.  25% of all 
TNBCs lack ER, PR, and HER2 in IHC but do not 
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exhibit the features of the basal-like subtype
 (22)
. Basal 
like breast cancer can be described by different 
combination of Immunohistochemical markers, in 
particular the lack of ER, PR, and HER-2 expression, 
associated with the expression of high-molecular weight 
basal cytokeratins (CK5/6, CK14, and CK17) or 
epidermal growth factor receptor (EGFR) 
(24)
. The 
majority of basal-like breast cancers is of high 
histological grade, high mitotic indices, with the 
presence of central necrotic or fibrotic areas and massive 
leukocyte infiltration 
(25)
. TP53 gene mutation is 
observed in up to 85% of cases; alterations of the pRB 
and p16 G1/S cell-cycle checkpoints are remarkably 
prevalent in these cancers. There is also increasing 
evidence of the presence of BRCA1 dysfunctional 
pathway in BLBC; indeed TNBC are enriched for germ-
line BRCA1 mutations
 (18) (26)
. Because of the lack of 
approved targeted therapy, at present chemotherapy 
remains the mainstay of treatment for early and 
advanced disease 
(15)
.  
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Table 1. 
 
 
 
Table 1 Breast cancer intrinsic subtypes with IHC profiles and treatment option.  
ER: estrogen receptor, PR: progesterone receptor, HER-2: human epidermal growth 
factor receptor2, IHC: immunohistochemistry.( Modified from Toss & Cristofanilli, 
2015.) 
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1.2 Tumor Associated Macrophages 
 
Solid tumors, such as breast cancer, are not considerable as 
single entities but are closely linked to their microenvironment 
that consists of a large variety of cellular and non-cellular 
components such as stromal cells, blood vessels and leukocyte 
infiltrate. Bidirectional interactions between tumor cells and the 
tumor microenvironment, that are necessary both for the normal 
tissue homeostasis and for tumor growth, affect cancer 
progression, response to treatment, patients prognosis
 (27)
. 
One of the most prominent stromal component of tumor 
microenvironment are macrophages, commonly termed tumor 
associated macrophages (TAMs), that has been largely 
demonstrated  to promote tumor progression supporting tumor-
associated angiogenesis, tumor cell invasion, migration and  
metastatization.  
Moreover, many different clinical studies, show that an 
increase in tumor-associated macrophages (TAMs) density is 
correlated with poor prognosis in breast cancer 
(28)
 
(29) 
, and 
subset of proliferating TAM populations are associated with 
high grade, hormone receptor negative breast cancers with poor 
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outcomes and can be considered predictors of recurrence and 
survival 
(30) (31)
. 
During tumor progression, circulating monocytes, originating as 
well as other macrophages in bone marrow, are actively 
recruited into tumors by the release of chemokines, cytokines, 
growth factors and hypoxia; once there, they differentiate in 
macrophages that can be polarized in alternative phenotypes in 
response to stimuli received, contributing to alter the tumor 
microenvironment with the release of different stimuli in turn
 
(32)
. The most important and characterized chemokine for  
monocytes recruitment in breast cancer is monocyte chemotactic 
protein-1 (MCP-1 or CCL2); indeed inhibition of CCL2-CCR2 
signaling impairs the recruitment of inflammatory monocytes as 
many studies demonstrate in breast cancer mouse model; also 
the depletion of tumor-derived CCL2 has been demonstrated to 
inhibit metastatization in murine models 
(33)
.  
In addition to CCL2 other chemokines as CCL3, CCL4, CCL5, 
CCL22 and CXCL8 have also been shown to be important for 
TAMs recruitment 
(32)
. Among the cytokines, macrophage 
colony stimulating factor 1 (M-CSF-1) plays an important role 
in regulate infiltration and polarization of TAMs. Indeed, an 
elevated CSF-1 level correlates with marked macrophage 
infiltration in human metastatic breast cancer; conversely, using  
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mice homozygous for CSF-1 null mutations, it has been 
demonstrated  that CSF-1 depletion leads to a marked reduction 
of the macrophages infiltrate that in turn determine a slower 
progression  of tumor growth and a better prognosis for mices 
both in lung and breast models 
(34) (35)
. 
However, growth factors including vascular endothelial growth 
factor (VEGF), endothelin 2, and platelet-derived growth factor 
(PDGF) have also been reported to promote 
monocyte/macrophage recruitment 
(36)
. 
Another important attractant for macrophages is the hypoxic 
environment in the tumor that,  in internal areas, releases 
chemo-attractants such as VEGF-A, Endothelin and Endothelial-
monocyte-activating Polypeptide II (EMAP-II) that stimulate 
macrophages to migrate in response to hypoxia. When 
macrophages reach hypoxic areas they are trapped in because of 
the hypoxic upregulation of Mitogen-activated Protein Kinase 
Phosphatase 1 (MKP-1) enzymes. 
MKP-1 dephosphorylates p44/p42 mitogen activated protein 
kinase (MAPK), extracellular signal-regulated kinase (ERK 1 
and 2, respectively) and p38 MAPK that require 
phosphorylation and thus activation to mediate migration of 
monocytes and monocytic cell lines in response to chemokines
 
(37)
. 
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1.2.1 Macrophages polarization 
 
Depending on the stimuli received from microenvironment  
macrophages can adopt a large variety of phenotypes that allow 
us to classify them in: 
1. Activated macrophages (AM), commonly referred as M1 
type  
2. Alternatively Activated Macrophages (AAM), 
commonly referred as M2 type 
Each polarized macrophage displays a differential expression 
profile of cytokines, enzymes, and cell-surface markers. 
Lipopolysaccharide (LPS) or Interferon gamma (IFN-γ) drive 
the macrophages differentiation in M1 phenotype that mainly 
participates in inflammatory response and antitumoral 
immunity. Indeed, M1 macrophages release pro-inflammatory 
cytokines as IL-6, IL-12, IL-23 and tumor necrosis factor α 
(TNF-α) and express high levels of major histocompatibility 
complex class I and II (MHC-I, MHC- II), so they can be 
considered potent effector cells of the immune system 
(38) 
. 
Conversely, the M2 macrophages exert anti-inflammatory and 
pro-tumorigenic activities; they also have poor ability to antigen 
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presenting and are involved in angiogenesis promotion, wound 
healing and tissue remodeling. In line with these functions, M2 
cells display high levels of scavenger, mannose and galactose 
type receptors. They can be further divided into subsets named 
M2a, M2b, M2c on the basis of the stimuli received; IL-4 or IL-
13 stimulate the polarization in M2a phenotype; the activation of 
Toll like receptors (TLRs) or IL-1 receptor (IL1-R) polarize 
macrophages in M2b phenotype; IL-10, glucorticoids and TGF-
β induce the M2c phenotypes (32) (38) (39) (Fig.1). 
Based on their functions within the tumor microenvironment, 
TAMs are generally characterized as M2-like macrophages, 
especially in the latter stage of cancer progression when they 
exert typical immunosuppressive, anti-inflammatory and pro-
angiogenic functions of the alternative macrophages phenotype; 
however many subpopulation with different functional states can 
coexist within the tumors, and probably it depends on their 
localization in tumor microenvironment and on the kind of 
stimuli received 
(39) (40)
. 
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Figure 1 Macrophages polarization. Schematic representation of the polarization of 
macrophages: LPS or IFN-γ drive M1 macrophage polarization that in turn release IL-
12 and IL-23. IL-4 and IL 13 polarize to M2a phenotype; activation of TLR by 
immune complexes or TLR-ligands polarize in M2b phenotype and IL-10, 
Glucocorticoids and TGFβ induce the M2c phenotype. (Modified from Obeid et al., 
2013). 
 
 
1.2.2 TAMs role in tumor progression 
 
TAMs have been shown to be involved in tumor progression 
promoting angiogenesis, tumor growth, invasion and metastasis.  
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 Angiogenesis: 
It is now well established that TAMs play a pivotal role in 
promoting the angiogenic switch that consists on the 
development of a tumor vasculature necessary to sustain the 
increased metabolic demand of a growing tumor. A study by Lin 
et al., in a mouse model of breast cancer caused by the 
mammary epithelial cell restricted expression of the Polyoma 
middle T oncoprotein (PyMT mice),  reported that the presence 
of macrophages in tumors, is positively associated with a high 
density of blood vessels; indeed depletion of macrophages, 
obtained using homozygous mice for a null mutation of CSF-1, 
determines a sensible reduction of vasculature in such tumor 
model 
(41)
. 
Extensive studies have established the role of TAMs in 
promoting tumor angiogenesis or vascularization through the 
production and release of many pro-angiogenic growth factors 
and cytokines including VEGF, TNF-α, interleukin-8 (IL-8) and 
enzymes such as matrix metalloproteinase (MMP-2, MMP-7, 
MMP-9, MMP-12) that contribute to regulate the angiogenic 
process. In particular, macrophagic VEGF production is mainly 
driven by the hypoxic activation of  Hypoxia inducible factor-1α 
(HIF-1A) that regulates the transcription of a large panel of 
angiogenesis related genes, including VEGF 
(37) (41)
. 
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VEGF expression itself is able to promote new vessels 
formation, even in CSF-1 null mice, but it also contributes to 
rescue macrophages recruitment that in turn stimulate the 
production of VEGF and other angiogenic factors underlining as 
macrophages play a pivotal role for angiogenesis. Macrophages 
are indeed responsible for VEGF supply both by its production 
and also by the production of MMP-9 that makes matrix-bound 
VEGF available, thus contributing to cell invasion 
(42)
. 
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Figure2. Soluble Factors and Hypoxia Mediating Monocyte/Macrophage 
Mobilization into Tumors. Mechanisms of monocytes/macrophages 
recruitment into tumors mediated by environmental factors such cytokines, 
chemokines, ECM and hypoxia. Hypoxic areas enhance macrophage release 
in response to low oxygen concentration, releasing  higher amount of 
chemoattractants such as EMAPII, endothelin, and VEGF-A; hypoxia also 
restrains macrophages by decreasing their mobility through the upregulation 
of MKP-1 enzymes and terminating  the macrophage response to 
chemoattractants outside the hypoxic areas. (Modified from Chanmee et 
al.,2014) 
 
 
Tumor growth, invasion and metastasis 
 
Among TAMs contributions  to tumor progression,  there  is 
also their ability to accelerate tumor growth by the expression  
and release of a large variety of factors that stimulate cell 
proliferation and survival, such as epithelial growth factor 
(EGF), PDGF, TGF-β and basic fibroblast growth factor (bFGF)  
(43)
. 
TAMs are also involved in the metastatic process that represents 
a crucial phase of cancer progression, and it occurs when tumor 
cells acquire specific capabilities to leave the primary tumor, 
invade the surrounding matrix, and  spread  to other sites 
through blood vessels; TAMs are believed to directly and 
indirectly affect the metastatic process of tumor cells by 
modulating the tumor microenvironment. 
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The intense production  of proteolytic enzymes like cathepsin B 
and S or MMPs, together with the evidence in PyMT induced 
mammary tumors of their tendency to localize along the 
basement membrane,  represent  important suggestions of their 
involvement in the degradation of the surrounding ECM 
allowing tumor cells to invade normal tissue crossing this barrier 
(44) (45). 
Considering their important role in tumor progression TAMs are 
widely considered a potential biomarker for prognosis of cancer 
as well as potential therapeutic targets. The expression of 
macrophage markers in different tumor tissues is generally 
associated with worse clinical prognosis as well as a high 
density of infiltrated TAMs is associated with aggressive 
features (46) (47). 
Therapeutic strategies against TAMs can be directed to restrict 
their recruitment into tumor tissue or their activation.  Several 
ongoing clinical trials employ drugs against the CCL2/CCR2 
axis that have proven to be effective in tumoral growth 
inhibition of several cancer models. CSF-1/CSF-1R signaling 
represent another target to limitate tumor recruitment and 
activation based on the evidence that Csf-1 null mice show 
slower progression  of tumor growth and a better prognosis for 
mices in different kind of tumors 
(48) (49)
. 
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1.3 ID family of proteins (ID-1 to 4) 
 
The  ID family of proteins (Inhibitors of Differentiation, ID-1 to 
4)  is a group of  dominant negative regulators of  basic helix-
loop-helix (bHLH) transcription factors. ID proteins lack the 
basic DNA-binding domain but maintain an intact HLH domain, 
so they can form heterodimers with bHLH transcription factors, 
inhibiting their ability to bind the DNA. Genes encoding ID 
proteins are paralogs well conserved amongst species, and they 
exert regulative role in different organisms maintaining high 
similarity in HLH domain 
(50)
.  
While the HLH domain is highly conserved between the four 
proteins, the N- and C- terminal domains result to be different in 
ID4 respect the others ID proteins; this difference is due in 
particular to the presence of a poly-alanine rich tract, between 
residues 39 and 54 at the N-terminal, that in ID4 is 
independently evolved compared to its paralogs ID1, ID2, ID3 
and that allow the ID4 N-terminal to adopt a helical 
conformation, differentiating ID4 from the others ID proteins. 
Another structural peculiarity of ID4 protein is a proline-rich 
region present in the C-terminus that seems to be involved in 
 24 
  
facilitating ID4 to form protein-protein interactions. It can be 
hypothesized that ID4 might exert unique functions through 
these structural features 
(51) (52)
. ID proteins expression decreases 
during differentiation, becoming lower in mature tissues than in 
stem and progenitor cells; these proteins were described initially 
as inhibitors of differentiation and more recently as regulators of 
cell cycle progression
 (53)
, senescence, apoptosis 
(54) (55)
 and 
tumorigenesis 
(56)
; moreover, depending on the cellular context 
in which they are expressed, ID proteins can exert opposite 
function, acting as oncoproteins or tumor suppressors
 (52)
. 
 
1.3.1 Inhibitor of DNA binding protein 4 (ID-4) 
 
Among ID proteins, ID4 in particular was shown to be involved 
in the differentiation of many cells including neurons 
(57)
 
adipocytes
 (58)
 and osteoblasts, and in mammary gland 
development
 (59)
. 
Its role as developmental regulator seems to contribute to confer 
stem-like properties such as strong renewal potential to 
transforming cells; such ability has been observed during the 
malignant transformation of primary murine astrocytes 
Ink4a/ARF−/−, where ID4 controls the expression of both 
Cyclin E and Jagged-1, driving the neural cells into a neural 
 25 
  
stem-like state
 (60)
. ID4 expression is found to be down-
regulated, usually through its promoter hyper-methylation, in a 
large variety of tumours including leukaemia, prostate cancer, 
gastrointestinal carcinomas and breast cancer
 (51)
 
(61)
; while in 
such tumours it probably act as oncosuppressor, it has been 
reported to be up-regulated in many other tumours as 
glioblastoma multiforme (GBM), basal-like breast cancer and 
ovarian carcinoma
 (62)
 
(63)
. 
 
 
1.3.2 ID4 IN BREAST CANCER 
 
Increasing evidences support a central role for ID4 in regulating 
mammary cell proliferation and lineage commitment. 
Transcriptome analyses by Lim et al. of mouse and human 
mammary cell subpopulations (e.g. luminal progenitors, 
committed/ mature luminal and basal cells) revealed that ID4 is 
one of the highest differentially expressed genes specific to 
basal cells 
(64)
.  
ID4 controls luminal commitment and mammary 
stem/progenitor cell self-renewal, by suppressing the expression 
of several key pathways involved in appropriate luminal 
epithelial commitment. Breast Cancer Type 1 susceptibility 
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protein (BRCA1), Notch signaling, ERα and FOXA-1 are 
inhibited in their expression by direct interaction of ID4 with 
their promoter region, while ELF-5 is indirectly inhibited 
through the Notch signaling. Many of these factors, such as 
BRCA1 and ELF5 are well known to be involved in breast 
cancer, evidencing as ID4 plays an important role in mammary 
tumorigenesis
 (65)
 . 
In particular, overexpression and amplification of ID4 has been 
reported in basal-like BRCA-1-mutated breast tumors and in 
ovarian cancer, and the complex regulatory network involving 
ID4, ERα and BRCA1 in these tumors still remains to be fully 
elucidated 
(66)
. BRCA1 and ERα mRNA expression have been 
shown to correlate in sporadic breast cancers, while ID4 is 
negatively correlated to both BRCA1 and ERα in sporadic 
basal-like breast cancer
 (63) (67) 
. 
However, in clinical breast cancer, ID4 expression is exclusive 
to ERα negative subtypes. Therefore, the role of ID4 in invasive 
breast cancer has been both tumor suppressive and oncogenic 
depending on the ER status 
(68)
. 
Regulation of ID4 expression in breast cancer is a field of 
intensive study. The expression of ID4 can be induced by 
mutant p53 protein, that is recruited in vivo to ID4 gene 
promoter regulatory regions, in association with p65 (NF-kB) 
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and the transcription factor E2F-1, favouring the recruitment of 
the acetyltransferase p300 that indicate an active chromatin 
status. 
(69)
. The activation of ID4 expression determines an 
enhancement of the angiogenic potential of mutant p53-carrying 
tumour cells. The mutant p53/ID4 axis promotes endothelial 
cells proliferation and migration in vitro. In addition, the 
analysis of human breast cancer cases revealed that a higher 
microvessels density is present in the ID4-positive population 
than in ID4-negative one. At the molecular level, ID4 protein is 
able to bind and stabilize the mRNAs of pro-angiogenic factors 
like CXCL8 (IL8) and CXCL1 (GRO-alpha), containing AU-
rich (ARE) elements in their 3‟UTR, resulting in a higher rate of 
translation of these transcripts
 (69)
 . 
Moreover, we recently identified ID4 to be part of a 
ribonucleoprotein complex containing mutant p53, the splicing 
factor SRSF1 and the long non-coding RNA Malat-1. Malat-1 
usually localizes to nuclear speckles where it modulates the 
activity of many splicing factors, including SRSF1 that has also 
been previously reported to control the expression of specific 
isoforms of VEGFA, a major player in tumour angiogenesis. 
SRSF1 bridges MALAT1 to mutant p53 and ID4 proteins in 
breast cancer cells, and  mutant p53 and ID4 in turn delocalize 
MALAT1 from nuclear speckles and favor its association with 
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chromatin. This enables aberrant recruitment of MALAT1 on 
VEGFA pre-mRNA and modulation of pro-angiogenic 121 e 
165 VEGFA isoforms expression
 (70)
 
 
 
 
Figure 3.  Recapitulation of ID4 functions in Breast cancer. A Inhibitor of 
differentiation 4 (ID4) promoter can be transcriptionally activated in vivo by mutant-
p53 in association with p65, E2F-1 and p300 (69) B ID4 exert angiogenic functions as 
part of a molecular complex, comprising mut-p53, lnc-Malat-1 and SRSF1, that drives 
the alternative splicing of VEGFA isoforms favouring the production of the pro-
angiogenic 165 e 121 (70) C Once synthesized ID4 protein is able to bind and stabilize 
the mRNAs of IL8 and  CXCL1 (GRO-alpha), resulting in a higher rate of  
translation of these pro-angiogenic cytokines transcripts (69). D ID4 expression is 
inversely correlated to the expression of BRCA1 leading to the enhancement of 
genomic instability (63).  E As reported in Junankar et.al, 2015  ID4 is a key controller 
of mammary stem/progenitor cell self-renewal, acting upstream of Notch signalling to 
repress luminal fate commitment (65). F TNBC and BLB C are the breast cancer 
subtypes presenting the highest ID4 expression (71) 
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2. AIM OF THE PROJECT 
 
 
Breast cancer is a heterogeneous disease, comprising a large 
variety of immune-histological, clinicopathological and 
molecular subtypes that show different behavior for incidence, 
survival and response to treatment. Among these subtypes, 
BLBC and TNBC are the most aggressive, due to the absence of 
targeted therapies and for the high probability of metastatization 
and recurrence in 3 years after therapy.  
It has been well established that the presence of a massive 
leukocytes infiltration, especially of TAMs, which characterizes 
BLBC and TNBC, is associated with a poor prognosis. Among 
the most characterized abilities of TAMs there is the 
acceleration of tumor progression through the activation of 
angiogenic pathways that contribute to the development of a 
tumor vasculature necessary to sustain the growing tumor.  
ID4 is a protein associated to stemness, proliferation and neo-
angiogenesis in human cancers and it is highly expressed and 
prognostic in TNBC and BLBC.  
 30 
  
The purpose of this study is to clarify the mechanisms through 
which ID4 controls angiogenesis in breast cancer. Starting from 
the observation that high ID4 expression in breast cancer cells is 
able to influence macrophage behavior in paracrine manner, we 
here investigated the molecular networks, comprising both 
mRNAs and microRNAs, controlling the ID4-dependent 
angiogenic program in tumor-associated macrophages. 
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3. RESULTS 
 
 
3.1 ID4 expression in BC cells influences 
macrophages recruitment  
 
We have previously shown that ID4 is able to drive the 
enhancement of angiogenic potential in breast cancer cells, as its 
expression is associated with an increase in the production of 
pro-angiogenic cytokines, as CXCL-1 (also known as GRO-
alpha) and IL-8, involved in the proliferation and migration of 
endothelial cell, and it is also associated with high microvessels 
density in BC 
(69) (70)
. 
As previously reported, macrophages are considered 
determinants of the onset of the angiogenic switch that is 
necessary for tumor progression 
(41) (43)
, therefore based on this 
and on the evident role of ID4 in angiogenesis, we wondered 
whether ID4 promotes angiogenesis also by influencing 
macrophages behavior and recruitment. 
We first evaluated if the expression of ID4 in breast cancer cells 
is able to influence the migratory capacity of murine bone 
marrow-derived macrophages; to this end we isolated CD34+ 
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progenitors from mouse bone marrow, differentiated in vitro to 
macrophages (Fig 4A) and allowed them to migrate in response 
to breast cancer cells depleted or not of ID4 expression (si- ID4 
or si- SCR) (Fig 4B). We observed that a lower number of 
macrophages migrated in response to si-ID4 breast cancer cells 
compared to control si-SCR cells (Fig 4C). We then evaluated 
whether ID4 expression in breast cancer cells is able to induce 
the recruitment of macrophages also in vivo. To this end we 
performed matrigel assays, by the use of matrigel plugs 
containing conditioned medium (CM) from MDA-MB-468 
breast cancer cells, transfected with an expression vector for 
HA-tagged ID4 or an empty vector as control, and inoculating 
plugs subcutaneously in mice flanks (Fig 4D-E). Matrigel plugs 
have been recovered after 7 days and stained by 
immunohistochemistry with mouse monocyte/macrophage 
marker F4/80, according to what previously reported 
(72)
. We 
observed a higher number of F4/80+ cells in plugs containing 
CM from ID4-overexpressing cells compared to control plugs 
(Fig 4F-G). 
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Figure 4 ID4 expression in breast cancer cells controls macrophages recruitment. 
A FACS analysis of differentiation markers in mouse bone marrow-derived before 
(T0) and after (T6) culturing in CSF-1 rich medium for 6 days. 
 B Western blot analysis of ID4 si-RNA interference in SKBR3 cells used for 
migration assay. C Trans-well migration assay of mouse bone marrow-derived 
macrophages in response to SKBR3 cells depleted (si-ID4) or not (si-SCR) for ID4 
expression. D Western blot analysis showing efficacy of transfection of ID4 vector 
HA-tagged compared with an empty vector transfection in MDA-MB468 cells used to 
prepare conditioned media (CM). E Schematic representation of Matrigel assay F 
Immunohistochemical analysis of mouse macrophage marker F4/80 on matrigel plugs 
containing MDA-MB468 CM, overexpressing or not ID4-HA. G Counts of F4/80+ 
cells from at least 3 biological replicates as mean +/- SEM ***p<0.0005 calculated by 
two-tailed t test. 
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3.2 ID4 expression correlates with macrophage 
recruitment in triple-negative breast cancer 
 
On the basis of the observed correlation between ID4 expression 
in breast cancer and tumor associated macrophages recruitment, 
we decided to evaluate whether any association existed between 
ID4 protein expression and infiltrating tumor-associated 
macrophages in human breast cancer. To this end we stained a 
series of 62 triple-negative breast cancers (TNBC), the breast 
cancer subtype showing the higher ID4 expression level among 
all breast cancer subtypes 
(71) 
(Fig 5 A-B) and in which high ID4 
expression is associated with low probability of survival 
(68) 
for 
ID4 protein and for the widely used macrophage marker CD68 
(73)
. Based on the expression of ID4 protein, detectable as 
expected in 75% of the specimens, we divided the analyzed 
population in ID4-low (comprising negative and scored as 1+ 
tumors) and ID4-high (comprising scored 2+ and 3+ tumors); 
CD68 staining was scored as the infiltration density and was 
evaluated as follows: 0 absent, 1+ mild, 2+ moderate, 3+ dense. 
We interestingly observed that high CD68 protein expression 
was significantly associated with the ID4-high group (P= 0.028) 
(Figure 5C). Moreover, we didn‟t find any association between 
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ID4 and CD68 and other clinical or pathological variables in this 
group of patients. Representative images of TNBC showing high 
or low protein levels of ID4 and CD68 are shown in Figure 5D. 
 
 
 
 Figure 5 Inhibitor of differentiation 4 (ID4) protein and macrophage marker 
CD68 are significantly associated in triple-negative breast cancer (TNBC). A-B 
Comparison of ID4 mRNA expression in BLBC and TNBC versus all other breast 
cancer subtypes(others) C-D Staining of 62 TNBC for ID4 protein and for the 
macrophage marker CD68. Fisher‟s exact test evidenced that ID4 and CD68 
expressions are significantly associated (P=0.028). D Representative images of TNBC 
showing high or low protein levels of ID4 or CD68. 
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3.3 ID4 expression predicts survival in tumors 
highly infiltrated by macrophages 
 
Both ID4 high expression and macrophages infiltrate have been 
correlated with angiogenesis and have been shown to have a 
prognostic value in breast cancer; but if ID4 expression in 
TNBC and BLBC has been associated with decreased survival, 
the prognostic value of macrophages is contradictory, probably 
for the existence of different populations infiltrated in the tumor 
with different properties 
(33) (65) (68)
. 
On this basis, we decided to investigate whether the expression 
of ID4 and the presence of macrophage infiltration in the tumor, 
are correlated with survival in BLBC cohorts of patients. To this 
end we interrogated the Kaplan- Meier Plotter database 
(www.kmplot.com), which contains a compendium of studies 
with gene expression and relative survival data for BLBCs.  
Interestingly, we observed that high ID4 expression was 
strongly associated with low probability of DMFS (n = 232)  
specifically in the group of tumors characterized by high 
expression of CD68 (and therefore highly infiltrated by 
macrophages) (Fig 6 A), whereas no association of ID4 with 
survival was present in the low-CD68 group (Fig. 6 B).  
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A similar result was obtained when a macrophage signature 
comprising a subset of eight widely used markers (CD14, 
CD105, CD11b, CD68, CD93, CD33, IL-4R and CD163) for the 
mononuclear phagocyte system was used to identify tumors 
highly infiltrated by macrophages (Fig 6 C-D). 
 
 
Figure 6. ID4 expression predicts survival in tumors highly infiltrated by 
macrophages. Kaplan-Meier analysis on kmplot database (A-D) of the predictive 
power of ID4 mRNA expression for distant metastasis-free survival (DMFS) (N = 
232) evaluated in basal-like breast cancer (BLBC) showing high or low CD68 (A-
B)or  macrophage signature (MacSig) levels (C-D) composed of eight widely used 
markers for the mononuclear phagocyte system (CD14, CD105, CD11b, CD68, 
CD93, CD33, IL4R, and CD163 
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Analysis of gene expression data from The Cancer Genome 
Atlas (TCGA) cohort of BLBCs confirmed that high ID4 
expression is associated to low probability of overall survival 
specifically in the CD68-high and macrophage signature 
(MacSig)-high groups (Fig 7 A-D). 
The TCGA cohort allowed us also to assess that ID4 and CD68 
do not associate with the clinical variables T, N and G, whereas 
ID4 significantly associates with mutated TP53 status. 
Moreover, because none of the considered patients from the 
TCGA cohort received neoadjuvant treatment, we can assert that 
the observed associations are independent of particular treatment 
regimens. These results indicated that the combination of ID4 
and macrophage markers represents a powerful predictive 
indicator in BLBC.  
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Figure 7 ID4 expression predicts survival in tumors highly infiltrated by 
macrophages Predictive power of ID4 mRNA expression for overall survival (OS) 
was evaluated by Kaplan–Meier analysis on the TCGA cohort in BLBCs showing 
high or low CD68 (A-B) or macrophage signature (MacSig) (C-D) levels. 
Macrophage signature is composed of eight widely used markers for the mononuclear 
phagocyte system (CD14, CD105, CD11b, CD68, CD93, CD33, IL4R, and CD163) 
 
 
3.4 ID4 expression in breast cancer cells 
determines ID4 induction in macrophages 
 
We next decided to evaluate whether the expression of ID4 
in BC was able to reprogram the gene expression of 
macrophages co-cultured with BC cells.  
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We first evaluated whether ID4 expression levels changed 
in monocytes/macrophages co-cultured with breast cancer 
cells compared to their monoculture. 
As shown in Figure 8A, ID4 mRNA was induced in a time-
dependent manner in human peripheral blood-derived 
monocytes (PBDM) grown in co-culture with SKBR3 
breast cancer cells. Similar results have been obtained 
culturing U937 monocytic cells, with conditioned medium 
(CM) from two BC cell lines (SKBR3 and MDA-MB-468) 
(Fig 8 B-C). Moreover the induction of ID4 expression was 
assessed in HL60 cell line, after 72 hours of differentiation 
in VitD3 
(74) (75)
, cultured with SKBR3 and MDA-MB-468 
CM, both by mRNA quantification and by 
immunocytochemistry (Fig 8 D-E). Interestingly using other 
macrophage stimuli (LPS, TNF-alpha, IL-4/IL-13) to 
culture the HL60 cell line, we didn‟t observe any induction 
of the expression of ID4, indicating that the effect is 
specifically dependent on the CM from breast cancer cells 
(Fig 8F). Moreover, the modulation of ID4 expression is 
specific of macrophages, as no modulation of ID4 was 
observed in human fibroblasts cultured in CM from BC 
cells. (Fig 8G-H). 
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Figure 8  ID4 expression in macrophages is induced by CM from breast cancer 
cells.  A. Time course of ID4 mRNA expression evaluated by RT-qPCR in PBMD co-
cultured with BC cells (SKBR3). B-C. Expression of ID4 mRNA in U937 cells after 
culturing in RPMI or BC cell lines CM. D. ID4 mRNA expression in HL60 cells 
cultured in RPMI medium or in CM from SKBR3 or MDA-MB468 cell lines  for 24h. 
E. ID4 protein was detected by immunocytochemistry (ICC) in HL60 cells cultured in 
RPMI medium or in CM from MDA-MB-468 (CM 468) cells for 24h. F. ID4 mRNA 
expression in HL60 cells cultured in CM from MDA-MB-468 cells or in RPMI 
medium containing the indicated macrophage-activating compounds [LPS 1μg/mL; 
TNF-alpha 50ng/mL; IL4/IL13 20ng/mL each]G-H. Human fibroblasts were grown 
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in presence of CM from MDA-MB-468 and SKBR3 cells and analyzed for ID4 
mRNA (G) and protein (H) expression. 
 
Moreover, a reduced ID4 induction in macrophages has 
been observed by culturing various macrophage 
experimental systems in conditioned medium from BC cells 
ID4-depleted by si-RNA transfection ( si-ID4- 1 and si-ID4- 
2) compared to control CM (si-SCR) (Fig 9A-E). On the 
contrary, using CM from ID4-overexpressing breast cancer 
cells we observed stronger induction of ID4 mRNA in 
PBDM than in the control CM (empty vector, EV) in a time 
dependent manner (Fig 9F); in the same experimental 
conditions also HL60 cell line showed similar induction 
both at mRNA and protein level. (Figure 9G-H). Altogether 
these results demonstrated that breast cancer cells 
determined an induction of ID4 expression in 
monocytes/macrophages that is strictly dependent on the 
ID4 expression levels in breast cancer cells. 
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Figure 9 ID4 expression in breast cancer cells determines ID4 expression 
induction in macrophages.  A ID4 mRNA expression on PBDM co-cultured with 
control (si-SCR) or ID4-depleted (si-ID4) SKBR3 cells for 48h. B-C ID4 mRNA 
expression in HL60 and Monomac cells cultured in RPMI medium or in CM from si-
SCR or si-ID4 MDA-MB-468 and SKBR3 cells. D ID4 mRNA expression in U937 
cultured in CM from si-ID4 MDA-MB-468 cells, versus si-SCR. E 
Immunocytochemistry analysis of ID4 protein levels in si- SCR vs. si-ID4 MDA-MB-
468 and SKBR3 cells used for CM preparation F ID4 mRNA expression on PBDM 
cultured in CM from control (EV) and ID4-HA-overexpressing MDA-MB-468 cells 
evaluated after 3 days or 6 days of culture. G-H ID4 mRNA (G) and protein (H) 
expression evaluated on macrophages obtained from HL60 differentiation and 
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cultured in CM from control (EV) or ID4-HA-overexpressing (ID4-HA) MDA-MB-
468 cells. **(P<0.005) P-values were calculated by two-tailed t-test. 
 
 
3.5 ID4 induction in macrophages depends on 
ID4 promoter activation 
 
To assess if the modulation of ID4 expression in macrophages, 
co-cultured with, or growth in the presence of CM from breast 
cancer cells, relies on the activation of endogenous ID4 
promoter, we evaluated the status of chromatin on the promoter 
of ID4 in macrophages by Chromatin Immunoprecipitation 
(ChIP) experiments. 
We cultured RAW 264.7 cells for 16 hours in CM from ID4 
over-expressing BC cells (CM ID4-HA) and in CM from BC 
cells transfected with an empty vector  (CM EV) as control, and 
we then analyzed the ID4 promoter by ChIP analysis using 
antibodies recognizing acetylation of histone H4 (H4Ac), 
correlated with an open chromatin status, and methylation of 
histone H3 lysine 9 (H3K9me3), highly correlated with 
constitutive heterochromatin. 
As well as the induction of ID4 mRNA in RAW 264.7 cultured 
in presence of CM from ID4-HA breast cancer cells (Fig 10 A), 
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we also observed a reduction in the methylation status of the 
lysine 9 of the histone H3 and an induction of the acetylation of 
the histone H4; altogether these results are indicative of an 
activation of the ID4 promoter in macrophages in dependence of 
the expression of ID4 in BC cells (Fig. 10B). 
 
 
 
Figure 10 The induction of ID4 expression in macrophages is an endogenous 
event occurring on the promoter of ID4. A ID4 mRNA induction in RAW264.7 
cells in presence of the conditioned medium from BC cells ID4-HA over-expressing 
compared with the expression of ID4 in presence of CM from EV transfected BC 
cells. B ChIP analysis of the ID4 promoter in RAW 264.7 cultured as in (D) using 
antibodies against the H3K9me3 and the H4Ac and normalizing the enrichment on a 
negative control genomic region. 
 
A B 
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3.6  ID4 expression in breast cancer cells 
determines the activation of a pro-angiogenic 
program in macrophages 
 
As one of the main activities of TAMs is to promote 
angiogenesis, we next explored whether ID4 expression in BC 
cells affects the expression of angiogenic genes in macrophages, 
using a TaqMan Low Density Array (TLDA) containing probes 
for a panel of 94 angiogenesis-related genes. Macrophages, 
obtained from HL60 differentiation, cultured with CM from 
MDA-MB-468 cells transfected with an ID4 expression vector 
(ID4) or an empty vector (EV), as well as control macrophages 
cultured in RPMI medium, were evaluated. In this experimental 
setting we detected 36 expressed genes amongst which 11 genes 
modulated in ID4-dependent manner and we validated in the 
same experimental conditions some of them (Ephrin B2, 
Midkine, Granulin, Edil3) by RT-qPCR (Fig. 11 A) and Western 
Blot (Fig. 11 C). Interestingly, the same subset of genes didn‟t 
result modulated in MDA-MB-468 cells overexpressing ID4 
(Fig 11 B). 
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Figure 11. A. Validation of subset of angiogenic genes modulated in macrophages 
in ID4-dependent manner (A-C) A Validation by RT-qPCR of subset of angiogenic 
genes modulated in TLDA in  differentiated HL60 cells cultured in CM from ID4 
overexpressing MDA-MB-468 cells or control (CM EV). B Subset of genes as in (A) 
analysed in MDA-MB-468 cells transfected with ID4 vector or empty vector (EV). C 
Western blot analysis for EphB2, MDK and GRN in HL60 cells cultured as in (A). 
 
 
Coherently, we observed an opposite effect in ID4-interference 
condition analyzing the expression a subset of the genes 
modulated in TLDA, comprising GRN, EphB2, NRP2; in 
addition to these we evaluated the expression of HIF1-A, a 
master regulator of angiogenesis 
(76) (77)
, and the expression of 
CXCL1 that we previously reported to be modulated by ID4 
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expression in breast cancer
 (69)
. Specifically, in U937 cells 
cultured with CM from MDA-MB-468 cells depleted of ID4 
expression (si-ID4) we observed a reduction of the mRNA 
induction of the selected genes (Fig. 12A) and a lower induction 
of the protein of GRN, HIF1A and EphB2, compared to control 
CM (si-SCR) (Fig. 12B-C). Interestingly, these results showed 
that ID4 expression in breast cancer cells is determinant to the 
activation of an angiogenic program in macrophages. 
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Figure 12 ID4 depletion in breast cancer cells determines down-regulation of 
angiogenic genes.  A Relative mRNA expression evaluated by RT-qPCR of a subset 
of genes modulated in the arrays comprising EphB2, GRN, NRP2, HIF- 1A, CXCL1, 
in U937 cells cultivated in control medium (RPMI) or  in conditioned medium from 
breast cancer cells ID4-depleted (si-ID4) or not (si-SCR). B Western blot analysis 
showing ID4 protein level after its depletion in MDA-MB-468 cells used to prepare 
the conditioned medium and the protein levels of EphB2, GRN and HIF- 1A in u937 
cells cultured in breast cancer cells si-SCR or si-ID4 conditioned medium. C 
Immunofluorescence analysis of HIF-1A protein performed in differentiated U937 
cells cultured in the presence of CM si-SCR or CM si-ID4 from MDA-MB-468 cells. 
 
Based on the evidence that the expression of ID4 in breast 
cancer cells is able to drive the activation of the expression of 
angiogenesis related genes in macrophages, we hypothesized 
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that the crosstalk between BC cells and macrophages could be 
exerted by a soluble factor released from breast cancer cells in 
ID4-dependent manner. 
In this regard, we recently reported that ID4 protein is involved 
in the synthesis of pro-angiogenic VEGFA isoforms in BC cells
 
(70)
,
 
so we postulated that the VEGFA could be responsible for 
the observed effects. To explore this hypothesis we first cultured 
differentiated U937 cells in CM from VEGFA-depleted (si-
VEGFA) or control (si-SCR) BC cells and analyzed a panel of 
angiogenesis-related factors evidencing a partial decrease of 
their expression after VEGFA depletion (Fig.13A - B). Next, we 
observed that the addition of VEGFA blocking antibody to the 
CM from BC cells subsequently used to culture U937 cells, 
partially impaired the induction of this panel of angiogenesis-
related factors (Fig.13C). These results indicated that ID4-
dependent gene expression modulation in macrophages is at 
least in part under the control of VEGFA signaling. 
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Figure 13 VEGFA partially mediates the crosstalk ID4 dependent between BC 
cells and macrophages. A Western blotting showing the efficiency of vascular 
endothelial growth factor A (VEGFA) depletion by si-RNA transfection in MDA-
MB-468 cells used to prepare CM used in experiments shown in B RT-qPCR analysis 
of the indicated messenger RNAs in U937 macrophages cultivated in the presence of 
CM from control (si-SCR) or VEGFA-depleted (si-VEGFA) MDA-MB-468 cells. C 
RT-qPCR analysis of the indicated genes in differentiated U937 cells cultivated in 
RPMI medium or in CM from MDA-MB-468 cells in the presence of VEGFA 
blocking antibody (Ab) or a control Ab. Specifically, VEGFA blocking Ab or control 
Ab were incubated with CM for 30 minutes at room temperature and CM plus Ab was 
subsequently used to culture U937 cells for 48 hours. Results from at least three 
biological replicates are shown. Data are presented as mean ± SEM. *P < 0.05, **P < 
0.005, ***P < 0.0005 calculated by two-tailed t test. 
3.7  ID4 expression in breast cancer cells down-
regulates anti-angiogenic microRNAs in 
macrophages 
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To fully explore the molecular mechanisms involved in the 
activation of the angiogenic program in macrophages, we 
hypothesized the presence of a post-transcriptional level of 
control by micro-RNAs; so we focused our attention on the 
members of the miR-15/107 group that has been previously 
correlated to angiogenesis and reported to target GRN and HIF- 
1B 
(78) (79) (80)
; so we evaluated their expression in macrophages 
cultured with BC cells conditioned medium. 
We observed that miR-107, miR-15b and miR-195 are down-
regulated in macrophages cultured with CM from ID4-
overexpressing BC cells (CM ID4) compared with macrophages 
cultured with CM from BC cells with control empty vector (CM 
EV) (Fig 14A). On the contrary, expression of these miRNAs 
was recovered in the presence of CM from si-ID4 BC cells in 
two macrophage cell lines U937 e HL60 (Fig 14B-G). We also 
evaluated the expression of miR-96, which exhibits oncogenic 
activity in BC
 (81)
, as a control of the specificity of the effect for 
our selected miRNAs, and we observed that it behaves in 
opposite manner, compared to miR-107 family members (Fig 
14E) indicating that the effect observed was specific for our 
selected miRNAs. 
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Figure 14 A Expression of miR-107, miR-15b and miR-195 in differentiated HL60 
cells cultured with CM from control (CM EV) or ID4-overexpressing (CM ID4) 
MDA-MB-468 cells. B, C, D, F, G, H Expression of miR-15b and miR-195 in HL60 
and U937 cells cultured with CM from control (si-SCR) or ID4-depleted (si-ID4) BC 
cells. E RT-qPCR for miR-96 in U937-derived macrophages as in B, C,D,F,G,H 
 
 
Recovery of miR-107, miR-15b and miR-195 expression was 
also observed in U937 cells cultured in the presence of CM from 
VEGFA-depleted BC cells indicating that VEGFA signaling 
also controls, at least in part, miRNAs expression in TAMs (Fig. 
15A). Next, we focused on miR-107, which shows the strongest 
ID4-dependent paracrine down-regulation in macrophages, and 
evaluated whether it affects the expression of GRN and HIF-1B, 
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two well-established targets  
(79) (80) (82)
. To this end, we inhibited 
miR-107 in U937 cells by transfecting an LNA oligonucleotide 
(Fig.15B). As shown in Fig.14 C miR-107 inhibition recovered 
GRN and HIF-1B protein expression, mimicking the effect of 
the CM derivated from breast cancer cells. 
We also observed induced protein expression of EphB2 and 
HIF-1A (Fig.15C), which, as the majority of the angiogenesis-
related factors that are activated in an ID4-dependent paracrine 
manner in macrophages, are predicted to be targeted by the miR-
15/107 group members. To further investigate the relevance of 
miR-107 down-regulation associated with CM, we 
overexpressed miR-107 using mimic oligonucleotides in 
macrophages cultured with CM from MDA-MB-468 BC cells 
(Fig.15D). The forced expression of miR-107 led to decreased 
GRN protein levels (Fig.15E) Similar results were observed for 
HIF-1A as showed by immunofluorescence analysis in Fig 15F. 
Our results indicated that the expression of angiogenesis-related 
genes is strictly controlled by the activity of the ID4-dependent 
miR-107 in macrophages. 
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Figure 15 A miR-107, miR-15b and miR-195 expression, evaluated by RT-qPCR, in 
differentiated U937 cells cultured with CM from MDA-MB-468 cells depleted or not 
of VEGFA expression. VEGFA interference efficiency is shown in Figure 12A. B 
RT-qPCR analysis of miR-107 levels in differentiated U937 cells transfected with 
locked nucleic acid (LNA) antisense oligonucleotide directed to miR-107. C Western 
blot analysis of the indicated proteins in differentiated U937 cells transfected with 
LNA antisense oligonucleotide directed to miR-107. D miR-107  expression levels 
evaluated by RT-qPCR in HL60 and U937 cells transfected with control mimic or 
miR-107 mimic oligonucleotides. E  Western blot analysis of GRN in HL60 
transfected with control mimic or miR-107 mimic oligonucleotides. Results from at 
least three biological replicates are shown. Data are presented as mean ± SEM. *P < 
0.05,**P < 0.005, ***P < 0.0005 calculated by two-tailed t test.  F HIF1A expression 
evaluated by immunofluorescence in differentiated U937 cells transfected with 
control mimic or miR-107 mimic and cultured in CM from MDA-MB-468 cells for 
48h 
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4.  Materials and methods 
 
 
4.1 Cell culture and reagents 
 
The SKBR3, MDA-MB-468, HL60 and U937 cell lines were 
obtained from the ATCC (Manassas, US) and cultured in RPMI; 
RAW 264.7 in DMEM (Gibco, Life Technologies, Carlsbad, 
CA, USA) supplemented with 10%  heat inactivated FBS (Life 
Technologies), 100 Units/mL Penicillin and 100 μg/mL 
Streptomycin (Life Technologies). Cell lines were grown at 
37°C in 5% CO2. DPBS (EuroClone, Milano, Italy) and Trypsin 
0.05% (GE Healthcare Hyclone, Little Chalfont, UK) were used 
to wash and detach cells. HL60 and U937 cells were 
differentiated by treatment with 1,25-dihydroxyvitamin D3 
(VitD3) (Sigma-Aldrich, St. Louis, MO, USA) at a 
concentration of 250 ng/ml. 
Mouse bone marrow–derived macrophage precursors were 
obtained from rodents by flushing the femurs and tibias with 2% 
FBS in PBS. Differentiation was obtained by culturing 
precursors in CSF1-rich conditioned medium derived from L929 
fibroblasts cell culture. Differentiation was evaluated by FACS 
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analysis using the following antibodies: anti-mouse F4/80 
antigen APC (17-4801; eBioscience), Ly-6G (Gr-1) APC (17-
5931; eBioscience, San Diego, CA, USA), CD14 PE (12-0141; 
eBioscience, San Diego, CA, USA) and CD107b (Mac-3) PE 
(12-5989; eBioscience, San Diego, CA, USA). 
Human peripheral blood derived monocytes (PBDM) were 
isolated from blood donors using Lymphoprep solution (AXIS-
SHIELD) followed by isolation of CD14+ cells with the 
Monocyte Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, 
Germany). Differentiation was obtained through a 1-week 
culturing in RPMI medium containing recombinant human 
CSF1. 
Breast cancer cells and macrophages were co-cultured using 0.4 
m-pore 6-well Boyden chambers (Corning).  Conditioned 
media (CM) from breast cancer cells were prepared by culturing 
cells for 24h in serum-free RPMI medium. CM were centrifuged 
to eliminate cell residues, before preparation of aliquots and 
storage at -80°C. 
Monocytic differentiation was assessed by fluorescence-
activated cell sorting (FACS) as previously reported
 (83)
 using 
allophycocyanin (APC) anti-human CD11b (BD Biosciences, 
San Jose, CA, USA), PerCP-Cy5.5 (peridinin chlorophyll 
protein complex-cyanine 5.5) anti-human CD14 (BD 
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Biosciences) and phycoerythrin-immunoglobulin G1 (PE-IgG1) 
isotype control (eBioscience Inc., San Diego, CA, USA) 
antibodies for the evaluation of CD11b-CD14 co-expression as a 
marker of monocytic differentiation. A minimum of 10,000 
events were collected for each sample with a flow cytometer 
(CyAN ADP; Beckman Coulter Life Sciences, Brea, CA, USA) 
using Summit 4.3 software (Beckman Coulter Life Sciences) for 
data acquisition and analysis.  
 
 
4.2 Cell transfection 
 
An expression vector containing a hemagglutinin (HA)-tagged 
ID4 coding sequence  or control empty vector was transfected in 
cancer cells using Lipofectamine 2000 reagent (Thermo Fisher 
Scientific, Waltham, MA, USA) in ID4 overexpression 
experiments. RNAiMAX reagent (Thermo Fisher Scientific, 
Waltham, MA, USA) was used to transfect small interfering 
RNAs (siRNAs) in BC cells. siRNAs were purchased from 
Eurofins MWG (Ebersberg, Germany). Monocytic cell lines 
were transfected with mimic oligonucleotides and locked 
nucleic acid (LNA) oligonucleotides (Dharmacon, Lafayette, 
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CO,USA) using TransIT- X2 Dynamic Delivery System  (Mirus 
Bio LLC, Madison, WI, USA) following  manufacturer‟s 
instructions. Si-RNA sequences used for ID4 silencing as 
follow: 
Scr- CTATAACGGCGCTCGATAT,  
ID4_1-GATCCTGCAGCACGTTATC,  
ID4_2 TTACAGAGCTCTTGATATC  
VEGFA si-RNA sequences are TriFecta, synthesized from 
Integrated DNA technologies (IdT). 
 
 
4.3 In vitro and in vivo macrophage migration 
assays 
 
Migration of mouse bone marrow–derived macrophages in 
response to SKBR3 cells was evaluated using 3 µm-pore 
Boyden chambers (Corning Inc., Corning, NY, USA). 
Infiltration of F4/80+ macrophages in Matrigel plugs containing 
CM from breast cancer MDA-MB-468 cells was evaluated by 
subcutaneous inoculation of a solution composed by 500 µl of 
matrigel (BD Bioscience) and 50 µl of 10X-concentrated CM. In 
the negative control, the CM was replaced with SFM. Plugs 
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were recovered at day 7, fixed for 18–24 hours in 4% (v/v) 
buffered formaldehyde and then processed through to paraffin 
wax. Immunohistochemistry was performed using F4/80 
antibody (MA5-16363; Pierce Biotechnology, Rockford, IL, 
USA). All procedures involving animals and their care were 
conducted in conformity with the institutional guidelines, which 
are in compliance with national and international laws. 
 
 
4.4 Immunohistochemistry, immunocytochemistry 
and immunofluorescence 
 
BC specimens for Immunohistochemistry analysis were fixed 
for 18–24 hours in 4% (v/v) buffered formaldehyde and then 
processed through to paraffin wax. Anti-ID4 (MAB4393, EMD 
Millipore, Billerica, MA, USA), anti-ER (clone 6F11, 
Novocastra, Menarini, Florence, Italy) anti-PgR (clone 1A6, 
Novocastra), anti-HER-2 (A0485; Dako, Milan, Italy), were 
evaluated by immunohistochemistry on 5-μm-thick paraffin-
embedded tissues. Monoclonal antibody directed against ID4 
was incubated at a dilution of 1:200 overnight at 4°C, and 
monoclonal antibodies (MoAb) anti-ER, anti-PgR and the 
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polyclonal antibody anti-HER-2 were incubated for 60 minutes 
at room temperature. Immunoreactions were revealed by a 
streptavidin-biotin enhanced immunoperoxidase technique 
(Super Sensitive MultiLink; BioGenex, Fremont, CA, USA) in 
an autostainer (Bond III; Leica Biosystems, Wetzlar, Germany). 
Diaminobenzidine (DAB) was used as a chromogenic substrate. 
Evaluation of the IHC data was performed independently and in 
blinded manner by 2 investigators (E.G. and M.E.). 
For immunocytochemistry assay, cells were seeded onto glass 
coverslips (Paul Marienfeld, Lauda-Königshofen, Germany) in 
6-well dishes (Corning Inc.) at 4 × 10
4
 cells/ well, cultured with 
RPMI or CM, and fixed with 4% formaldehyde in PBS for 15 
minutes at room temperature. Cells were permeabilized with 
0.25% Triton X-100 in PBS for 10 minutes. After washing with 
PBS, the coverslips were incubated with anti-ID4 antibody 
diluted in 5% bovine serum albumin (BSA)/PBS for 2 hours at 
room temperature. Cells were incubated with peroxidase 
inhibitor before primary antibody incubation. Protein staining 
was revealed through DAB enzymatic reaction, and nuclei were 
counterstained with haematoxylin.  
For immunofluorescence, cells grown in the presence of RPMI 
or CM (48 hours), as well as cells transfected with mimic 
oligonucleotides (48 hours), were concentrated onto microscope 
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slides using cytospin and fixed and permeabilized as already 
described. Slides were blocked for 30 minutes in 5% BSA/PBS 
at room temperature and then incubated with an anti-HIF-
1Aantibody (A300-286A; Bethyl Laboratories, Montgomery, 
TX, USA) diluted in 5% BSA/PBS for 2 hours at room 
temperature. Cells were incubated with secondary antibody 
Alexa Fluor 594 (1:500; Thermo Fisher Scientific) for 45 
minutes. Nuclei were stained with DAPI (Thermo Fisher 
Scientific). 
 
4.4 Western blotting and antibodies 
 
For the Western blot analysis, cells were lysed on ice for 30 
minutes in radioimmunoprecipitation assay buffer (RIPA),  
supplemented with protease and phosphatase inhibitors (1 mM 
CI, 5 mM PMSF, 1 mM DTT, 1 mM Na2VO4), or in urea 8M at 
room temperature. Cell lysates were sonicated and  the protein 
concentration was measured using a Bio-Rad protein assay kit 
(Bio-Rad Laboratories, Hercules, CA, USA).  The lysate was 
mixed with 4 ×  Laemmli buffer. Equal amounts of total protein 
extracts were resolved on 10% or 15%  denaturing SDS 
polyacrylamide gel electrophoresis and then transferred onto 
nitrocellulose membrane. Membranes were blocked with 5%- 
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milk-TBS 0.05% Tween-20 for 2 h and incubated overnight 
with specific primary antibodies.  The following primary 
antibodies were used: Gapdh (sc-32,233), ID4 (H70) sc-13047, 
ID4 (B5) sc-365656, HA (12CA5) sc-57592 (Santa Cruz 
Biotechnology, Dallas, TX, USA); HIF-1A (A300-286A; Bethyl 
Laboratories); GRN (PA5-29909), EphB2 (PA5-14607), Mdk 
(PA5-30601; Thermo Fisher Scientific), HIF-1B (clone 1A1, 
Origene). Secondary antibody fused with horseradish peroxidase 
was used for chemiluminescence detection on a UVITEC 
instrument (Uvitec, Cambridge, UK). VEGFA blocking 
antibody (AF-293-NA; R&D Systems, Minneapolis, MN, USA) 
was added to CM and incubated for 30 minutes at room 
temperature before being used to culture macrophages, 
following the manufacturer‟s instructions.  
 
4.5 RNA isolation, RT-qPCR and TaqMan Low 
Density Arrays (TLDA) 
 
RNA was isolated with TRIzol reagent (Sigma-Aldrich), 
following the manufacturer‟s instructions and its concentration 
was measured using a NanoDrop 2000 instrument (NanoDrop 
Technologies, Wilmington,DE, USA). Reverse transcription was 
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performed with Moloney murine leukemia virus reverse 
transcriptase (Thermo Fisher Scientific). Rt- qPCR was carried 
out on an ABI PRISM 7500 Fast Sequence Detection System 
(Applied Biosystems, Foster City, CA, USA). The expression 
values of mRNAs were calculated by the standard curve method 
and normalized with housekeeping control genes (GAPDH, β-
actin, H3). RT- qPCR using TaqMan Low Density Arrays 
(TLDA) Human Angiogenesis (4378725; Thermo Fisher 
Scientific) was carried out following the manufacturer‟s 
instructions on an ABI PRISM 7900HT Sequence Detection 
System.  The following primers were used: 
 
 
Table 2 
ID4 
F 5‟ GTGCGATATGAACGACTGCT 3‟ 
R 5‟ CAGGATCTCCACTTTGCTGA 3‟ 
EphB2 
F 5‟: CGTGGAAGAAACGCTAATGG 3‟ 
R 5‟- : TGACTCAAACACGTTGCACA -3‟ 
NRP2 
F 5‟ GTCTCCTACAGCCTAAACGGCA-3‟ 
R 5‟ GGGTCAAACCTTCGGATGTCAG 3‟ 
HIF 1A 
F 5‟ ATCTGCAGGTCCCCATTCAA 3‟ 
R 5‟ ATGTGTGTGTGTCGTGTGTG 3‟ 
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VEGFA 
(all 
isoforms) 
F 5‟ CTTCCTACAGCACAACAAATGTG 3‟ 
R 5‟ GTCTTGCTCTATCTTTCTTTGG 3‟ 
RPL19 
F 5‟- CGGAAGGGCAGGCACAT -3‟ 
R 5‟- GGCGCAAAATCCTCATTCTC- 3‟ 
GAPDH 
F 5‟ -GAGTCAACGGATTTGGTCGT -3‟ 
R 5‟- GACAAGCTTCCCGTTCTCAG-3‟ 
Beta- 
ACTIN 
 
F 5‟- GGCATGGGTCAGAAGGATT- 3‟ 
R 5‟- CACACGCAGCTCATTGTAGAAG-3‟ 
CXCL1 
F 5‟-GCGCCCAAACCGAAGTC-3‟ 
R 5‟- TGCAGGATTGAGGCAAGCTT- 3‟ 
GRN 
F 5‟- CAGTGGGAAGTATGGCTGCT- 3‟ 
R 5‟- TTAGTGAGGAGGTCCGTGGT- 3‟ 
MDK 
F 5‟- CCTGCAACTGGAAGAAGGAG- 3‟ 
R 5‟- CTGGCACTGAGCATTGTAGC- 3‟ 
H1H2 BA 
 
F 
 
5‟-ACTCTCCTTACGGGTCCTCTTG- 3‟ 
 
 
R 
 
5‟-AGTGCTGTGTAACCCTGGAAAA- 3 
ID4 
murine 
promoter 
F 5‟-AAGCAAATTGCGGGCGGGGA- 3‟ 
R 5‟- CGGGCTCACCGCCTTCATCG- 3‟ 
  
Table 2 RT-PCR primers 
 66 
  
 
4.6 Chromatin immunoprecipitation assay 
 
Cells were cross-linked using 1% formaldehyde for 10 min at 
room temperature before the reaction was stopped by the 
addition of 0.125M Glycine, and washed three times with ice-
cold PBS. Cells were lysed in Buffer A (5 mM Pipes pH 8, 85 
mM KCl, 0.5% NP-40, 1 mM CI), centrifuged at 400 RCF for 
10 min at 4°C, resuspended in Buffer B (1% SDS, 10 mM 
EDTA, 50 mM Tris-HCl pH 8) and sonicated to shear DNA to 
lengths of approximately 200 bp. The chromatin solution was 
immunoprecipitated with rabbit anti-H3K9Me3 (Abcam), H4Ac 
(Abcam) or IgG (Santa Cruz) as negative control. IPs were 
performed using  Protein A/G magnetic beads (Thermo Fisher 
Scientific, Rockford,IL, USA). The immunoprecipitated and 
purified chromatin was subjected to quantitative PCR analysis 
(qPCR). Data were normalized to the amount of Input 
chromatin.  
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5.  DISCUSSION 
 
 
 
TAMs are considered important players in solid tumor 
progression and, in particular in breast cancer, their presence as 
part of the leukocyte infiltrate can be considered predictor of 
poor outcome, recurrence, survival and it has been associated 
with high grade, hormone receptor negative breast cancers 
(31) 
(73)
. ID4 high levels have been previously correlated with 
decreased survival in BLBC and TNBC 
(23) (65)
.  Here we 
demonstrated that the presence of high ID4 expression is 
predictor of poor outcome for overall and distant metastasis free 
survival specifically in BLBC cohorts showing high macrophage 
infiltration ( Fig. 6e 7). 
In this study we also demonstrated that ID4 in is able to induce 
macrophage migration and recruitment in BC and that its 
expression in breast cancer cells determined a reprogramming of 
macrophages gene expression, leading to induction of  
angiogenesis related genes.  
Interestingly, we observed that ID4 was able to modulate its 
own expression in macrophages co-cultured with breast cancer 
cells, and we determined that it was a macrophage-specific 
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event that did not involve other stromal cells such as fibroblasts, 
and that it occurred through an activation of ID4 promoter. This 
enhancement in ID4 expression in macrophages could lead to 
the recapitulation of one of the main ID4 functions in breast 
cancer cells, the pro-angiogenic one, that has been previously 
reported to be exerted by ID4 through both favoring the 
production of CXCL-1 and IL-8 cytokines and the production of 
proangiogenic VEGFA isoforms, finally enhancing micro-
vessels density 
(69)
; so it will be interesting to further investigate 
whether also ID4-expressing macrophages recapitulate ID4-
dependent functions.  
 In parallel to ID4 expression induction in macrophages, we 
observed a strong modulation of a panel of angiogenesis-related 
genes, among which there are some important regulators of  
inflammation and angiogenesis as Granulin, CXCL-1 and HIF-
1A. 
In particular Granulin captured our interest because since its 
initial discovery it has been revealed to be an important 
molecule in a wide variety of disease processes. GRN level is 
considered a prognostic biomarker for many forms of cancer as 
PGRN overexpression is associated with cancer cell 
proliferation and migration 
(84)
. 
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Moreover, it is a growth factor that is specifically expressed in 
TNBC and BLBC where it has been positively correlated to 
aggressiveness and chemoresistance
 (85)
. 
In macrophages, GRN has been reported to control cytokines 
production, but its effect on the angiogenic potential of these 
cells has been only characterize to its function in wounds repairs 
in mice, where it has been reported to increase fibroblasts, 
macrophages and capillaries that enter the wounds 
(86)
, and only 
recently it has been reported to contribute to angiogenesis in 
mesothelioma 
(87)
. 
It has been extensively explored GRN‟s role in inflammation 
since it is a potent inhibitor of the inflammatory cytokine tumor 
necrosis factor-a (TNF-alpha); it has been indeed reported that 
GRN directly binds to tumor-necrosis-factor receptors (TNFR-1 
and TNFR-2) and counteracts the TNF-mediated inflammatory 
signaling pathway. GRN also induces T-cell populations 
(88)
 and 
IL-10 production and inhibits CXCL-9 and CXCL-10 
chemokines release 
(89) (90)
 
Of note we determined that also HIF-1A shows an ID4-
dependent behavior in macrophages. HIF-1 A is the most 
important transcription factor involved in the cellular response 
to low oxygen concentration, and it has been previously reported 
to be up-regulated by hypoxic macrophages to in turn up-
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regulate a broad array of genes, including VEGF, whose 
production promotes angiogenesis 
(91) (92)
. HIF-1A has been also 
demonstrated to be induced by other stimuli than hypoxia, such 
as growth factor, hormones, and viral proteins 
(93)
 and in 
macrophages by LPS stimulation 
(94)
. Here, we depicted an ID4 
dependent modulation of HIF-1A in macrophages in an 
hypoxia- independent manner underlining as ID4 could promote 
neo-angiogenesis even in non-hypoxic regions of the tumor. 
Interestingly, the majority of the angiogenesis-related factors 
presents HIF-1A consensus sequences in their promoter regions 
as we assessed by the study of the promoter sequences using the 
algorithm to predict transcription factors binding sites, TFBs 
LASAGNA 2.0 (Table 3).  
Of note we identified as soluble mediator of breast cancer cells 
and tumor-associated macrophages cross-talk, the VEGFA, that 
we demonstrated to be almost in part responsible to the 
activation of the angiogenic program in macrophages co-
cultured with breast cancer cells. We have previously reported 
that ID4 participate to the control of VEGF isoforms production, 
in association with a molecular complex comprising mut-p53, 
SRSF1 and the lncMALAT-1 in breast cancer cells; this 
ribonucleoprotein complex drives the alternative splicing of 
VEGFA to the enhancement of pro-angiogenic VEGFA 
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isoforms, VEGF121 and VEGF165
 (70)
.  We depleted VEGFA 
both by si-RNA silencing in breast cancer cells used to prepare 
the conditioned medium, and by the use of blocking antibodies 
in the CM from BC cells. Using both this conditioned medium 
to culture macrophages, we observed a significant reduction in 
the expression of a panel of angiogenesis related genes, in 
particular of GRN, EphB2, NRP2 and HIF-1A. As that the 
depletion of both VEGFA and ID4, reduced the CM dependent 
activation of these genes in macrophages, it probably 
demonstrate that in macrophages the angiogenic program could 
depend on the ribonucleoprotein complex that mediate the 
VEGF isoforms production in BC cells. 
Interestingly, we showed that blocking of VEGFA prevents CM-
dependent activation of EphB2 and NRP2, among others.  
Of note, EphB2 has been shown to control VEGFR-2 
internalization that is necessary for  activation and downstream 
signaling of the receptor 
(95)
; NRP2 has been also demonstrated 
to be necessary to potentiate the activity of pro-angiogenic 
cytokines including VEGF-A165 acting as co-receptor for 
VEGFR 
(96)
.  Activation of EphB2 and NRP2 then could 
represent a mechanism for VEGFA signaling amplification in 
macrophages, because an increase of these molecules will 
probably lead to a more efficient response to the VEGFA 
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present in the CM (in our experimental system) and in the in 
vivo tumor microenvironment.  
Moreover, we identified a post-transcriptional level of control of 
the angiogenesis related genes involving the miR-15/107 group 
of miRNA, that has been previously reported to regulate  
angiogenesis in particular through  miR-107 
(97)
. 
MiR-107 has been previously reported, in colon cancer, to 
inhibit HIF-1beta (also known as aryl hydrocarbon receptor 
nuclear translocator, ARNT) that act as dimerization partner of 
HIF-1A in controlling cellular response to hypoxia 
(79)
; it has 
also been reported to target GRN 
(78) (82)
 in neuroglioma cells 
with implications to neurodegenerative disease such as 
Alzheimer disease, and in human cancer. 
Here we observed that miR-107, miR-15b and miR-195  are 
downregulated in macrophages co-cultured with BC cells. This 
downregulation is stronger in macrophages co-cultured with 
breast cancer cells expressing high levels of ID4 and is indeed 
impaired with the CM from ID4 depleted BC cells.  We also 
demonstrated that VEGFA signaling in part controls miRNAs 
expression in macrophages as observed by the recovery of miR-
107, miR-195, miR-15b in U937 cells cultured with CM from 
breast cancer cells VEGFA depleted.  
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We also confirmed in macrophages that GRN, HIF-1A and HIF-
1beta are post-transcriptionally controlled by miR-107 and we 
also demonstrated EphB2 to be subjected to the same miR-107 
control. Our study elucidates a novel role for these miRNAs in 
the  control of the angiogenic program in TAMs. 
 
Table 3 
Gene 
Symbol 
HIF-1 
consensus 
on 
promoter 
 
n° of 
databases 
predicting 
miR-107 
dependence 
n° of 
databases 
predicting 
miR-15b 
dependence 
n° of 
databases 
predicting 
miR-195 
dependence 
ANGPTL4 Yes 3(CDS) - - 
ECGF1 Yes - - - 
EDIL3 Yes 6(3‟UTR), 
2(CDS) 
2(CDS) - 
EPHB2 Yes 4(3‟UTR), 
2(CDS) 
4(3‟UTR), 
4(CDS) 
5(3‟UTR), 
4(CDS) 
FN1 No 5(CDS) 4(CDS) 5(CDS) 
GRN Yes 3(CDS) 6(CDS) 6(CDS) 
MDK Yes - -  
NRP2 Yes 8(3‟UTR), 
2(CDS) 
9(3‟UTR), 
6(CDS) 
9(3‟UTR), 
5(CDS) 
PRL Yes 3(CDS) 5(CDS) 4(CDS) 
VEGFB Yes 2(CDS) 3(3‟UTR), 
5(CDS) 
4(3‟UTR), 
5(CDS) 
VASH1 Yes 6(3‟UTR) - 3(3‟UTR) 
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Table 3 .Presence of HIF-1 consensus sequences on promoters of angiogenic-genes 
modulated in HL60 in ID4 dependent manner as assessed by TLDA,  was evaluated 
using the web tool http://biogrid-lasagna.engr.uconn.edu. Presence of putative binding 
sites for miR-107. miR-15b and miR-195 on 3‟-UTR or coding (CDS) sequences of 
mRNAs was evaluated using the miRWalk analysis tool (http://zmf.umm.uni-
heidelberg.de/apps/zmf/mirwalk2/) by selecting the following databases: 1) 3‟-UTR 
analysis= miRWalk, miRanda, miRDB, miRNAMap, Pictar2, RNA22, RNAhybrid, 
Targetscan; 2) CDS analysis= miRWalk, miRanda, RNA22, RNAhybrid, Targetscan. 
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6. CONCLUSION 
 
 
 
Altogether our results give additional insights to ID4 ability to 
control angiogenesis in breast cancer not only by the 
enhancement of the production of pro-angiogenic cytokines as 
we previously reported
 (69)
 but also by the reprogramming of 
tumor associated macrophages. We identified a paracrine 
signaling between breast cancer cells and tumor associated 
macrophages that could represent a promising basis for the 
development of targeted therapies aimed at blocking the cross 
talk between BC cells and the tumor microenvironment. 
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7. ABBREVIATIONS 
 
APC: Allophycocyanin 
BC: Breast cancer 
BLBC: Basal-like breast cancer; 
BRCA1: Breast cancer susceptibility genes 1; 
ChIP: Chromatin Immunoprecipitation analysis; 
CM: Conditioned media; 
CSF-1: Colony stimulating factor-1 
DAB: Diaminobenzidine;  
DMFS: Distant metastasis free survival; 
ECM: Extracellular matrix; 
ER: Estrogen receptor; 
EV: Empty vector;  
FACS: Fluorescence-activated cell sorting; 
GRN: Granulin; 
HA: Hemagglutinin; 
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HER-2: human epidermal receptor growth factor- 2 
HIF: Hypoxia-inducible factor; 
ID: Inhibitors of differentiation;  
IFN: Intefereron; 
IHC: Immunohistochemistry 
IL-n : Interleuchin 
LNA: Locked nucleic acid;  
LncRNA: long non coding RNA 
LPS: Lipopolysaccharide 
MacSig: Macrophage signature;  
miRNA, miR: MicroRNA;  
MMP: Matrix metalloproteinase; 
mut-p53: Mutant p53; 
mRNA: Messenger RNA; 
PBDM: ePripheral blood-derived monocytes; 
PDGF: Platelet-derived growth factor; 
PR: Progesteron receptor; 
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OS: Overall survival;  
RT: Room temperature;  
RT-qPCR: Realtime quantitative polymerase chain reaction 
si-ID4: ID4-depleted breast cancer cells; 
si-RNA: Small interfering RNA; 
si-SCR: Control breast cancer cells; 
SRSF1: Serine/arginine-rich splicing factor 1; 
TAM: Tumor-associated macrophage;  
TGF-β: Transforming growth factor; 
TLDA: TaqMan Low Density Array; 
TLR: Toll-like Receptor; 
TNBC: Triple-negative breast cancer;  
TNF: Tumor necrosis factor; 
TP53: tumor protein 53; 
UTR: Untranslated region;  
VEGFA: Vascular endothelial growth factor A; 
VitD3: 1,25-dihydroxyvitamin D3 
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